newsfilter
← Latest News
GlobeNewswire·

Liquidia Corporation Reports First Quarter 2026 Financial Results

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between